Metabolix Company Profile (NASDAQ:YTEN)

About Metabolix (NASDAQ:YTEN)

Metabolix logoYield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.

Industry, Sector and Symbol:
  • Sector: Consumer Staples
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:YTEN
  • CUSIP: N/A
  • Web:
  • Market Cap: $11.95 million
  • Outstanding Shares: 3,454,000
Average Prices:
  • 50 Day Moving Avg: $2.73
  • 200 Day Moving Avg: $2.24
  • 52 Week Range: $0.25 - $9.03
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.43 million
  • Price / Sales: 8.36
  • Book Value: $0.78 per share
  • Price / Book: 4.44
  • EBIDTA: ($8,950,000.00)
  • Net Margins: -190.57%
  • Return on Equity: -145.04%
  • Return on Assets: -81.21%
  • Debt-to-Equity Ratio: 0.47%
  • Current Ratio: 1.42%
  • Quick Ratio: 1.42%
  • Average Volume: 26,420 shs.
  • Beta: 3.59
  • Short Ratio: 1.73

Frequently Asked Questions for Metabolix (NASDAQ:YTEN)

What is Metabolix's stock symbol?

Metabolix trades on the NASDAQ under the ticker symbol "YTEN."

When did Metabolix's stock split? How did Metabolix's stock split work?

Shares of Metabolix reverse split on the morning of Tuesday, May 30th 2017. The 1-10 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Metabolix stock prior to the reverse split would have 10 shares after the split.

How were Metabolix's earnings last quarter?

Metabolix, Inc. (NASDAQ:YTEN) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.96) earnings per share for the quarter. The business earned $0.29 million during the quarter. Metabolix had a negative net margin of 190.57% and a negative return on equity of 145.04%. View Metabolix's Earnings History.

Who are some of Metabolix's key competitors?

Who are Metabolix's key executives?

Metabolix's management team includes the folowing people:

  • Robert L. Van Nostrand, Chairman of the Board, Independent Director
  • Oliver P. Peoples Ph.D., President, Chief Executive Officer, Director
  • Charles B. Haaser, Chief Accounting Officer, Vice President - Finance
  • Lynne H. Brum, Vice President - Planning and Communications
  • Kristi Snell Ph.D., Chief Science Officer, Vice President - Research
  • Sarah P. Cecil, General Counsel, Secretary
  • Richard William Hamilton Ph.D., Director
  • Joseph H. Shaulson, Director
  • Peter N. Kellogg, Independent Director
  • Anthony J. Sinskey Sc.D, Independent Director

Who owns Metabolix stock?

Metabolix's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Birchview Capital LP (7.94%) and Cannell Peter B & Co. Inc. (2.56%). View Institutional Ownership Trends for Metabolix.

Who sold Metabolix stock? Who is selling Metabolix stock?

Metabolix's stock was sold by a variety of institutional investors in the last quarter, including Birchview Capital LP and Cannell Peter B & Co. Inc.. View Insider Buying and Selling for Metabolix.

How do I buy Metabolix stock?

Shares of Metabolix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Metabolix's stock price today?

One share of Metabolix stock can currently be purchased for approximately $3.46.

MarketBeat Community Rating for Metabolix (NASDAQ YTEN)
Community Ranking:  1.3 out of 5 (star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  132
MarketBeat's community ratings are surveys of what our community members think about Metabolix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Metabolix (NASDAQ:YTEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Metabolix (NASDAQ:YTEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/9/2016HC WainwrightReiterated RatingBuyN/AView Rating Details
2/9/2016Rodman & RenshawInitiated CoverageBuy$30.00N/AView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for Metabolix (NASDAQ:YTEN)
Earnings by Quarter for Metabolix (NASDAQ:YTEN)
Earnings History by Quarter for Metabolix (NASDAQ YTEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2017Q2 2017($0.96)$0.29 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.70)$0.32 millionViewN/AView Earnings Details
11/9/2016Q116($1.40)($0.50)$0.47 millionViewListenView Earnings Details
5/16/2016Q1($2.30)($2.40)$0.89 million$0.68 millionViewN/AView Earnings Details
3/29/2016Q415($2.40)($2.20)$0.92 million$0.50 millionViewListenView Earnings Details
11/10/2015Q315($2.60)($2.20)$0.71 millionViewListenView Earnings Details
8/12/2015Q215($2.60)$0.74 millionViewListenView Earnings Details
5/13/2015Q115($0.40)($0.40)$0.65 millionViewListenView Earnings Details
3/19/2015Q414($0.90)($0.50)$0.86 millionViewListenView Earnings Details
11/5/2014Q3 14($1.60)($1.40)$1.10 million$0.63 millionViewListenView Earnings Details
8/6/2014($2.30)($2.10)$1.40 million$1.17 millionViewN/AView Earnings Details
5/14/2014($2.10)($2.30)$1.25 million$1.07 millionViewN/AView Earnings Details
3/27/2014($2.10)($2.50)ViewN/AView Earnings Details
11/5/2013Q3 13($2.40)($2.10)ViewN/AView Earnings Details
7/31/2013Q2 2013($2.00)($2.30)$1.57 millionViewN/AView Earnings Details
5/8/2013Q1 2013($2.50)($2.00)$1.43 million$1.94 millionViewN/AView Earnings Details
3/26/2013Q4 2012($2.60)($2.80)$1.23 million$1.40 millionViewN/AView Earnings Details
11/1/2012($2.40)($2.30)ViewN/AView Earnings Details
7/26/2012($2.60)($2.30)ViewN/AView Earnings Details
4/26/2012$8.40$8.40ViewN/AView Earnings Details
3/6/2012($3.00)($2.80)ViewN/AView Earnings Details
11/1/2011($2.90)($2.80)ViewN/AView Earnings Details
7/27/2011($3.30)($3.30)ViewN/AView Earnings Details
4/27/2011($3.60)($3.60)ViewN/AView Earnings Details
3/9/2011($3.70)($3.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Metabolix (NASDAQ:YTEN)

No earnings estimates for this company have been tracked by


Dividend History for Metabolix (NASDAQ:YTEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Metabolix (NASDAQ:YTEN)
Insider Ownership Percentage: 13.00%
Institutional Ownership Percentage: 9.21%
Insider Trades by Quarter for Metabolix (NASDAQ:YTEN)
Insider Trades by Quarter for Metabolix (NASDAQ:YTEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2016William P ScullyMajor ShareholderSell68,333$0.33$22,549.89View SEC Filing  
9/9/2016William P ScullyMajor ShareholderSell165,000$0.35$57,750.00View SEC Filing  
9/17/2015William P ScullyMajor ShareholderBuy31,833$2.11$67,167.63View SEC Filing  
9/15/2015William P. Scullymajor shareholderBuy67,500$2.16$145,800.00View SEC Filing  
9/10/2015William P ScullyMajor ShareholderBuy25,000$2.71$67,750.00View SEC Filing  
9/8/2015William P ScullyMajor ShareholderBuy40,000$2.23$89,200.00View SEC Filing  
9/4/2015William P. Scullymajor shareholderBuy42,750$2.15$91,912.50View SEC Filing  
8/28/2015William P ScullyMajor ShareholderBuy26,600$1.99$52,934.00View SEC Filing  
6/19/2015Birchview Capital Gp, LlcDirectorBuy43,700$3.32$145,084.00View SEC Filing  
6/19/2015Family Foundation SchulerMajor ShareholderBuy1,664,840$3.32$5,527,268.80View SEC Filing  
6/19/2015Joseph H ShaulsonCEOBuy35,000$3.32$116,200.00View SEC Filing  
6/19/2015Lynne H BrumVPBuy14,570$3.32$48,372.40View SEC Filing  
6/19/2015Walsem Johan VanCOOBuy12,000$3.32$39,840.00View SEC Filing  
11/29/2013Matthew StrobeckDirectorBuy100,000$1.00$100,000.00View SEC Filing  
12/3/2012Richard P EnoCEOBuy20,000$1.17$23,400.00View SEC Filing  
11/30/2012Nostrand Robert L VanDirectorBuy20,000$1.07$21,400.00View SEC Filing  
11/30/2012Oliver P PeoplesVPBuy40,000$1.07$42,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Metabolix (NASDAQ:YTEN)
Latest Headlines for Metabolix (NASDAQ:YTEN)
DateHeadline logoYield10 Bioscience to Participate in U.S. Department of Energy Grant for Boosting Oilseed Yield in Camelina - September 15 at 11:57 AM logoYield10 Bioscience Obtains Confirmation of Nonregulated Status from USDA-APHIS for its Genome-edited Camelina Line - September 5 at 3:34 PM logoYield10 Bioscience Obtains Confirmation of Nonregulated Status from USDA-APHIS for its Genome-edited Camelina Line - September 5 at 3:34 PM logoZacks: Metabolix, Inc. (YTEN) Given Consensus Rating of "" by Analysts - August 29 at 2:16 AM logoMetabolix, Inc. (NASDAQ:YTEN) Releases Quarterly Earnings Results - August 11 at 11:50 AM logoYield10 Bioscience Announces Second Quarter 2017 Financial Results - August 11 at 9:21 AM logoYield10 Bioscience Announces Collaboration with National Research Council of Canada to Improve Yield and Drought Tolerance in Wheat - August 9 at 9:31 AM logoYield10 Bioscience to Host Webcast of its Second Quarter 2017 Conference Call - July 27 at 9:49 AM logoYield10 Bioscience Announces Pricing of $2.3 Million Registered Direct Offering - July 3 at 8:43 AM logoYield10 Bioscience to Report Results Showing that Trait C4001 Produces Significant Increases in Plant Yield - June 28 at 3:44 AM logoYield10 Bioscience CEO Dr. Oliver Peoples to Present at BIO 2017 - June 20 at 9:25 AM logoYield10 Bioscience Submits “Am I Regulated?” Letter to USDA-APHIS BRS for Genome-Edited Camelina - June 15 at 4:15 PM logoYield10 Bioscience to Present at the Marcum Microcap Investor Conference - June 14 at 4:29 PM logoYield10 Bioscience Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement - June 14 at 2:26 AM logoReviewing Yield10 Bioscience (YTEN) and Curis (CRIS) - June 11 at 7:53 AM logoYield10 Bioscience (YTEN) versus Icon Plc (ICLR) Head-To-Head Contrast - June 10 at 10:52 PM logoYield10 Bioscience Starts Field Tests of Novel Yield Trait Gene C3003 in Oilseed Crops Camelina and Canola - June 9 at 2:56 AM logoHead to Head Review: Icon Plc (ICLR) & Yield10 Bioscience (YTEN) - June 8 at 4:10 PM logoYield10 Bioscience Starts Field Tests of Novel Yield Trait Gene C3003 in Oilseed Crops Camelina and Canola - June 8 at 2:16 AM logoYield10 Bioscience to Present at the SeeThruEquity Microcap Investor Conference - May 30 at 3:16 PM logoYield10 Bioscience, Inc. :YTEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017 - May 27 at 6:57 AM logoYield10 Bioscience Announces 1-for-10 Reverse Stock Split - May 26 at 9:08 AM logoYield10 Bioscience, Inc. 2017 Q1 - Results - Earnings Call Slides - May 12 at 3:20 PM logoYield10 Bioscience Inc (YTEN) Announces Quarterly Earnings Results - May 12 at 12:14 PM logoYield10 Bioscience Announces First Quarter 2017 Financial Results - May 11 at 8:25 PM logoYield10 Bioscience to Present at Joseph Gunnar Pioneers 2017 Conference - April 27 at 11:27 AM logoYield10 Bioscience to Host Webcast of its First Quarter 2017 Conference Call - April 26 at 5:24 PM logoYield10 Bioscience, Inc. Presentation Now Available for On-Demand Viewing - April 10 at 8:19 PM logoYield10 Bioscience, Inc. :YTEN-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017 - April 7 at 1:41 PM logoYield10 Bioscience, Inc. to Webcast, Live, at April 6 - April 4 at 5:22 AM logoYIELD10 BIOSCIENCE, INC. Files SEC form 10-K, Annual Report - March 30 at 8:39 PM logoYield10 Bioscience Announces Fourth Quarter and Full Year 2016 Financial Results - March 23 at 9:03 AM logoYIELD10 BIOSCIENCE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and - March 23 at 9:03 AM logoYield10 Bioscience to Host Webcast of its 2016 Year-end Conference Call - March 15 at 6:16 AM logoYield10 Bioscience Outlines Plans for Spring 2017 Field Tests of Novel Yield Trait Gene C3003 in Camelina and Canola - March 13 at 8:30 PM logoYield10 Bioscience Reports Promising Greenhouse Results for Second Generation C3003 Trait in Camelina - March 10 at 6:55 AM logoYield10 Bioscience to Present at 29th Annual ROTH Conference - March 6 at 8:08 PM logoYield10 Bioscience Expands Scientific Team with Two Key Hires - February 17 at 8:47 AM logoUniversity of Missouri Grants Yield10 Bioscience an Exclusive Option to Evaluate Advanced Technology for Oilseed Crops - February 1 at 7:37 AM logoYield10 Bioscience Reports Preliminary 2016 Camelina Field Test Results Showing that the C3003 Trait Produces Significant Improvements in Seed Yield - January 27 at 6:56 AM logoYIELD10 BIOSCIENCE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - January 27 at 6:56 AM logoYield10 Bioscience to Host Investor Conference Call - January 24 at 9:02 PM logoYIELD10 BIOSCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers - January 17 at 12:07 PM logoYIELD10 BIOSCIENCE, INC. Financials - January 17 at 12:07 PM



Metabolix (YTEN) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff